Overview

A Open-Label, Multiple Ascending Dose Study of DS-3078a, an Oral TORC1/2 Kinase Inhibitor, in Subjects With Advanced Solid Tumors or Lymphomas

Status:
Completed
Trial end date:
2014-06-01
Target enrollment:
Participant gender:
Summary
DS-3078a will be evaluated as a single agent in subjects with advanced solid tumor malignancies or lymphomas refractory to standard treatment or for which no standard treatment is available.
Phase:
Phase 1
Details
Lead Sponsor:
Daiichi Sankyo Inc.
Daiichi Sankyo, Inc.